###### Strengths and limitations of this study

-   The novel data reported in this study answer an important clinical question around asthma referral rates in primary care in England and may help us in the planning and implementation of improved healthcare services for people with asthma.

-   Other strengths of the study include the use of a large data set and its breadth of coverage, as well as the use of a conservative approach to exclude missing data and the long study duration (mean follow-up period of 5.47 years).

-   A limitation of the study may have been only using referral eligibility criteria (exacerbation frequency/medication use) based on the British Thoracic Society/Scottish Intercollegiate Guidelines Network guidelines, which may have omitted other rare causes of referral and could have led to a slight underestimation of the unmet need overall.

Introduction {#s1}
============

Asthma is a common and complex chronic inflammatory disease of the airways, which can lead to a significant burden for both individuals and society.[@R1] Appropriate management can reduce the risk of acute asthma attacks and airway remodelling while improving symptom burden and quality of life.[@R2] One key aspect of asthma management is timely referral of patients with difficult-to-treat asthma for a specialist opinion. Patients receiving care from asthma specialists have relatively low rates of hospitalisation and the potential for improved clinical outcomes, and the care provided is more likely to be consistent with national guidelines.[@R4] Asthma specialists have more topic-specific training, more time allocated to spend with patients and greater access to a broader range of tests than primary care clinicians. These factors are combined with access to additional healthcare resources and advanced therapies in a closely regulated and audited manner.[@R5] Referral can therefore lead to improved identification and remediation of factors that exacerbate asthma, including common comorbidities and treatment non-adherence, and an overall broad and effective care plan for patients.

Asthma management guidelines and recommendations provide guidance on when patients with asthma should be referred to a specialist.[@R8] Despite these guidelines, lack of specialist referrals or failure to refer in practice is evident: a review of asthma management in the USA found that even though the majority of patients were uncontrolled, only 22% of patients visited a specialist for usual asthma care.[@R10] Improvements in overall (global) asthma mortality rates have stalled over the last decade,[@R11] something which timely referral to specialist care may help to address. Indeed, the National Review of Asthma Deaths (NRAD) report identified that 19% of asthma deaths in the UK were associated with potentially avoidable factors related to specialist referral, such as delayed referral and failure to refer.[@R12] However, little is known about how many patients meet the criteria for referral from primary care. This information could help identify the potential burden on secondary care services and help with resource allocation and workforce planning.

In this study, we aimed to compare primary care asthma referral patterns with guideline recommendations and thereby identify the unmet need in asthma referrals in England. We defined unmet need as the number of patients who are eligible for referral to a respiratory specialist in England, based on asthma management guidelines and recommendations, but who had not yet been referred. The primary objectives of this study were to quantify this unmet need, identify the proportion of those eligible patients who were referred and determine the waiting time to their first referral.

Methods {#s2}
=======

Data source {#s2-1}
-----------

This observational cohort study was based on routinely collected healthcare data provided by Clinical Practice Research Datalink (CPRD)[@R13] and Hospital Episode Statistics (HES)[@R14] records from January 2007 to December 2015. CPRD is a primary care database with anonymised records from general practitioners (GPs) and covers over 11.3 million patients in the UK, of which 4.4 million patient records (alive and currently registered) meet the quality criteria (data quality is driven by the Quality and Outcomes Framework in the UK and monitored by CPRD internal processes); this constitutes approximately 6.9% of the UK population from across the country.[@R13] The HES database contains details of admissions, emergency department attendances and outpatient appointments at National Health Service (NHS) hospitals in England, and has patient-level linkage to approximately 60% of CPRD practices.[@R14] Given the broad coverage of CPRD and HES records, results of this study are expected to be nationally representative of the overall population of England. For this study, we have linked primary care records and practice-level socioeconomic status (index of multiple deprivation) from CPRD and admitted patient care and outpatient data from HES.

Study population {#s2-2}
----------------

The study population consisted of all patients with an asthma diagnosis who were registered with a GP during the study period. Inclusion criteria for the study were adult patients aged 18--80 years at study start, either with a pre-existing diagnosis or who had been newly diagnosed with asthma during the study according to asthma diagnostic Read codes ([online supplementary table 1](#SP1){ref-type="supplementary-material"}),[@R16] and with one full year of data prior to the index date (defined as the last day of the 3-month period for assessing baseline treatment regimen; please see below for further details). This 1-year minimum look-back period was to ensure that patients' medical history and any relevant comorbid conditions could be assessed. Patients must have been registered at a CPRD practice with acceptable quality standard records (quality flag derived from an algorithm considering gender, birth year, events prior to birth year, extreme age values, missing data and registration dates in general practice) and belong to practices consenting for linkage with HES data. Patients participating in a clinical trial during the study period (as determined by Read codes) or with a diagnosis code of chronic obstructive pulmonary disease within 1 year prior to index were excluded.
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Study design {#s2-3}
------------

Individuals were entered into the study from January 2007 or subsequently once they met eligibility criteria. At baseline, treatment stages were assessed during the first 3 months of observation (ie, study start plus 3 months) or within 3 months of diagnosis for patients diagnosed during the study period, using pharmacological therapy Read codes (which are available on request). The last day of the 3-month baseline assessment period was termed the 'index date'. For analysis, patients were assigned to pharmacological therapy categories based on the British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) 2016 guidelines. Patients only on a single regular preventer or low-dose inhaled corticosteroids (ICS) with an initial add-on therapy were excluded. The final cohort only included patients who were on either 'additional add-on therapies', 'high-dose therapies' or 'continuous or frequent use of oral steroids' (at least two prescriptions within the 3-month assessment period with a duration of ≥28 days; treatment details are shown in [table 1](#T1){ref-type="table"}).

###### 

Categorisation of patients by pharmacological therapy during the 3-month assessment period

  Category                                                            Treatment options
  ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  Additional add-on therapies (previously step 3**\***)               LABA+1 or more: LTRA, LAMA, theophylline or chromonesICS+1 or more: LABA, LTRA, LAMA or theophyllineLABA, LTRA, LAMA, theophylline or chromones
  High-dose therapies (previously step 4**\***)                       ≥800 µg ICS/LABA≥800 µg ICS≥800 µg ICS+1 or more: LABA, LAMA, LTRA or theophylline
  Continuous or frequent use of oral steroids (previously step 5\*)   ≥800 µg ICS, OCS+other treatment

ICS are in BDP equivalent dose.

\*Corresponding names of categories in the 2014 British Thoracic Society/Scottish Intercollegiate Guidelines Network guidelines.

BDP, beclomethasone dipropionate; ICS, inhaled corticosteroids; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonists; OCS, oral corticosteroid.

In the 2014 BTS/SIGN guidelines, these categories were known as step 3 (for additional add-on therapies), step 4 (for high-dose therapies) and step 5 (for continuous or frequent use of oral steroids).[@R17] Follow-up began at the index date and continued until the first of either end of registration in practice, end of study or death ([figure 1](#F1){ref-type="fig"}).

![Study design of UNTWIST. Patients were observed from the index date (last day of the 3-month period for BTS/SIGN assessment) until the first of either end of study period, death, patient's transfer out of practice or practice last collection date. To be eligible, patients had to have data for one full year prior to the index date (12-month look-back period). BTS/SIGN, British Thoracic Society/Scottish Intercollegiate Guidelines Network.](bmjopen-2019-031740f01){#F1}

Based on the BTS/SIGN 2016 guideline recommendations, patients were identified as eligible for referral if they were on 'high-dose therapies' or 'continuous or frequent use of oral steroids'. Patients could also have 'incident eligibility' during the follow-up period if they had continuous oral corticosteroid (OCS) use for \>3 months, or high-dose ICS/long-acting β~2~-agonists (LABAs) (or three controller medications) and ≥2 asthma attacks in a year (based on asthma Read codes).

Outcomes {#s2-4}
--------

The primary outcome of the study was to estimate the unmet need in asthma referral, that is, the proportion of eligible patients not referred, and the waiting time patients experienced between eligibility and their first referral. A list of Read codes was used to screen the CPRD referral records to identify the eligible patients who were referred during the study period ([online supplementary table 2](#SP1){ref-type="supplementary-material"}). The secondary outcome was to identify predictors of a patient's time to referral.

Statistical, survival and sensitivity analysis {#s2-5}
----------------------------------------------

Analysis was carried out to compare baseline characteristics between age groups, gender and treatment stages; a χ^2^ test was performed and 95% CI calculated. Histograms and percentages were used to display data. Survival analysis models were used to estimate predictors of the time to referral for a patient. Sensitivity analyses were performed with additional definitions of unmet need and waiting time ([online supplementary figure 1](#SP1){ref-type="supplementary-material"}).

This study was reviewed and approved by the Independent Scientific Advisory Committee for Medicines and Healthcare products Regulatory Agency database research (Ref: 17_026R) and an internal scientific committee of the study sponsor.

Patient and public involvement statement {#s2-6}
----------------------------------------

Neither patients nor the public were involved in the design or planning of the study.

Results {#s3}
=======

Cohort selection and baseline characteristics {#s3-1}
---------------------------------------------

At study start (January 2007), 1152982 patients with recorded asthma diagnosis who were aged 18--80 years and registered with a CPRD practice were identified. Of these, 23293 patients were included in the final cohort after exclusion criteria were applied, with the majority of patients receiving high-dose therapies ([figure 2](#F2){ref-type="fig"}). The final study cohort was composed of 60% females; the mean age of the population at index was 50 years (SD=14 years); 57% of the cohort had a body mass index (BMI) ≥25 kg/m^2^, and 28% of the cohort reported being current smokers. Distribution of patients across most regions of England was roughly even, with a similar percentage of patients across all three categories of 'additional add-on therapies', 'high-dose therapies' and 'continuous or frequent use of oral steroids' ([table 2](#T2){ref-type="table"}). Patients were equally spread across the five deprivation quintiles. The mean follow-up time for individuals was 5.47 years (SD=2.92 years).

###### 

Demographics and baseline characteristics of study cohort

  ----------------------------------------------------------------------------------------------------------------------------
  Baseline characteristics                                   All patients\   Medication category                 
                                                             (n=23293)                                           
  ---------------------------------------------------------- --------------- --------------------- ------------- -------------
  Female, n (%)                                              13879 (60)      2471 (65)             10855 (58)    553 (63)

  Mean age at index, (SD)                                    50 (14)         50 (14)               50 (14)       53 (13)

  BMI (kg/m^2^), n (%)                                                                                           

   Underweight                                               272 (1)         51 (1)                203 (1)       18 (2)

   Normal weight                                             4710 (20)       783 (21)              3751 (20)     176 (20)

   Overweight                                                6092 (26)       988 (26)              4886 (26)     218 (25)

   Obese                                                     5796 (25)       922 (24)              4633 (25)     241 (27)

   Severely obese                                            1378 (6)        235 (6)               1079 (6)      64 (7)

  Smoking status, n (%)                                                                                          

   Current smoker                                            6610 (28)       955 (25)              5392 (29)     263 (30)

   Non-smoker/never                                          13618 (58)      2335 (61)             10779 (58)    504 (57)

   Ex-smoker                                                 2961 (13)       512 (13)              2337 (13)     112 (13)

  Region, n (%)                                                                                                  

   North East                                                528 (2)         79 (2)                423 (2)       26 (3)

   North West                                                4208 (18)       600 (16)              3463 (19)     145 (16)

   Yorkshire and The Humber                                  1139 (5)        146 (4)               964 (5)       29 (3)

   East Midlands                                             942 (4)         95 (2)                815 (4)       32 (4)

   West Midlands                                             2912 (13)       479 (13)              2317 (12)     116 (13)

   East of England                                           2402 (10)       485 (13)              1815 (10)     102 (12)

   South West                                                3079 (13)       567 (15)              2357 (13)     155 (18)

   South Central                                             3283 (14)       475 (12)              2669 (14)     139 (16)

   London                                                    2356 (10)       412 (11)              1879 (10)     65 (7)

   South East Coast                                          2444 (10)       478 (13)              1894 (10)     72 (8)

  Mean number of OCS prescriptions in the year prior, (SD)   2 (5)           3 (7)                 2 (3)         12 (12)

  Mean eosinophil count (×10^9^/L), (SD)                     0.24 (0.13)     0.24 (0.13)           0.24 (0.13)   0.24 (0.14)

  Asthma attacks in the year prior,\                                                                             
  n (**%**)                                                                                                      

   1                                                         1492 (6)        275 (7)               1074 (6)      143 (16)

   2 or more                                                 489 (2)         124 (3)               260 (1)       105 (12)

  1+ asthma hospitalisations in the year prior, n (%)        872 (4)         138 (4)               666 (4)       68 (8)
  ----------------------------------------------------------------------------------------------------------------------------

BMI, body mass index; OCS, oral corticosteroid.

![Cohort selection and referral eligibility of patients in UNTWIST. ^a^For a description of investigated treatment regimens, see [table 1](#T1){ref-type="table"}. COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice Research Datalink; GP, general practitioner; HES, Hospital Episode Statistics; RCT, randomised controlled trial.](bmjopen-2019-031740f02){#F2}

Eligibility for referral to respiratory specialist {#s3-2}
--------------------------------------------------

Eligibility criteria based on the BTS/SIGN 2016 guidelines was applied to the final cohort of 23293 patients during the follow-up period and 19837 patients were identified as eligible for specialist referral: 9% of patients from 'additional add-on therapies', and all patients from 'high-dose therapies' or 'continuous or frequent use of oral steroids' ([figure 2](#F2){ref-type="fig"}).

Unmet need for asthma referral during the follow-up period {#s3-3}
----------------------------------------------------------

Among the patients who were eligible for referral, 85% (n=16875) had never been referred based on full medical records; of these, 723 (4%) patients had their first referral during the study period (16% of patients from 'additional add-on therapies', 4% of patients from 'high-dose therapies' and 8% of patients from 'continuous or frequent use of oral steroids') ([figure 3](#F3){ref-type="fig"}). For baseline characteristics of eligible patients without prior referral who were referred versus patients who were not referred, see [online supplementary table 3](#SP1){ref-type="supplementary-material"}.

![Unmet need for referral: referrals among patients who were eligible for referral for their asthma and had not previously been referred. Each block represents all the patients in the study who were eligible for referral and had not previously been referred.](bmjopen-2019-031740f03){#F3}

Time waiting for first referral to respiratory specialist {#s3-4}
---------------------------------------------------------

The median waiting time from eligibility (index date or date of incident eligibility) to the date they were referred was 880 days (IQR=1428 days; [figure 4](#F4){ref-type="fig"}).

![Waiting time to first referral during the follow-up period between 2007 and 2015 for eligible patients without any previous referrals, n=628. Total represents all patients who were eligible for referral without any previous referrals and had their first referral during the follow-up period between 2007 and 2015.](bmjopen-2019-031740f04){#F4}

Factors associated with time waiting for referral {#s3-5}
-------------------------------------------------

A longer waiting time for referral was associated with higher BMI (p\<0.001), deprivation quintile (deprivation was calculated based on patient postcode; longer waiting times in more deprived areas; p\<0.001), prescription of OCS (any use of OCS prior to index; patients with a prescription had a higher waiting time; p=0.031), index season (longest waiting time during January--March compared with October--December; p\<0.001), regional location (variation in waiting times across locations; p\<0.001) and index year (decreasing waiting times for more recent referrals; p\<0.001).

Sensitivity analyses {#s3-6}
--------------------

A sensitivity analysis for eligibility for referral---using a definition of eligibility based solely on 'incident eligibility' during the follow-up period (ie, unstable patients as indicated by continuous use of OCS for \>3 months, or use of high-dose ICS/LABA (or three controller medicines) and ≥2 asthma attacks in a year), and not including all 'high-dose therapies' and 'continuous or frequent use of oral steroids' patients automatically---identified 1617 patients (7% of final cohort) as eligible for referral ([online supplementary figure 1](#SP1){ref-type="supplementary-material"}). Among those who had their first referral during the study period (n=232, 14%)---using the above definition for referral eligibility---the median wait time was 861 days (IQR=1363 days).

A separate sensitivity analysis for those receiving a referral---in which referrals were analysed by a broader range of Read codes (compared with a more restrictive list for the main analysis), including referral records containing asthma diagnosis codes ([online supplementary table 1](#SP1){ref-type="supplementary-material"})---showed that 11% (n=2154) of all eligible patients were referred, with a median wait time to first referral of 1048 days (IQR=1490 days; [online supplementary figure 1](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

This study identified that a large number of patients were eligible for referral to respiratory specialists based on pharmacological therapy and exacerbation frequency as per the BTS/SIGN guideline recommendations. Of those eligible patients, only a small proportion (4%) were referred to specialist care during the study period and many experienced a long wait before this happened. This appears to indicate a major unmet need in asthma care.

Numerous national and international guidelines and recommendations for asthma management, such as the Global Initiative for Asthma (GINA),[@R8] BTS/SIGN guidelines[@R18] and, in England, the National Institute for Health and Care Excellence (NICE) asthma quality standard,[@R19] provide indications for specialist referral that broadly agree with the criteria for referral eligibility that we have used in our study.[@R18] Despite such alignment in referral recommendations, our large-scale study suggests that patients with asthma are not being referred to specialists appropriately. This is consistent with findings from the NRAD study.[@R12] The novelty in the design of our study, using nationally representative CPRD and HES data to estimate the unmet need in asthma referrals in England, adds to the findings of the NRAD study which used a smaller data set. Potential omission of further rare criteria for referral may mean that our study slightly underestimates the unmet need, although this gives the best overall estimate to date.

Suboptimal referral patterns are not unique to asthma. Other studies have found lower than expected referral rates for psoriasis,[@R20] delayed referral for symptomatic gallstones[@R21] and wide variation in referral rates for suspected gastrointestinal cancers.[@R22] Addressing this variation is central to initiatives such as Getting It Right First Time in the UK (<http://gettingitrightfirsttime.co.uk>).

Previous studies have identified factors relating to clinician behaviour,[@R8] financial pressures,[@R24] lack of coordination between different components of the healthcare system,[@R25] and patient attitude and expectations[@R26] as potential barriers to referral. It could also be that people with lower dose treatments experiencing exacerbations are more likely to be seen in secondary care than those who receive higher dose treatments but do not have frequent contact with healthcare professionals or unplanned admissions. In this study, deprivation quintile and regional location of patients were identified as predictors of longer waiting times to referral. These are consistent with findings from other studies that identified factors affecting waiting time for surgeries,[@R27] and in England may be explained by regional differences in access to NHS services. We also found higher BMI to be associated with longer waiting time to referral: one explanation for this could be due to the overattribution of symptoms to obesity itself,[@R29] thereby leading to a delay in onward referral or in progressing asthma management.

To address this unmet need, actions such as improving knowledge of referral criteria,[@R30] incentivising early review[@R31] and joint protocols between primary and secondary healthcare[@R25] might be initiated, as these have been shown to be effective in other countries. Initiatives such as the SIMPLES algorithm can be used in primary care to guide comprehensive review of patients to clarify which patients should be referred.[@R32] The algorithm involves assessment of smoking status, inhaler technique, monitoring (by both healthcare professionals and patients themselves), pharmacotherapy, lifestyle, education and the support needs of patients, and can act as a 'red flag' system in the primary care setting to proactively identify and systematically review patients on high-dose therapies, especially those who fail to achieve asthma control or have frequent exacerbations.[@R32] This can help prevent inappropriate treatment escalation, stepping down treatment where necessary, and identify patients for referral as per guideline recommendations. However, such initiatives must also be balanced against available provision of specialist resources. Improved targeting of those patients most likely to benefit from review will require further evidence-based research. There are 1.86 adult respiratory physicians per 100000 people in the UK, which is below the European mean of 4.4 adult respiratory physicians per 100000 people.[@R33] A large upswing in specialists might be needed to meet current guideline recommendations and address the backlog of asthma referrals identified in this study.

Our sensitivity analysis showed that if we limit eligibility to 'incident eligibility' criteria alone (see the Methods section for full definition), 7% of the final cohort is deemed eligible for referral, of which only 14% were referred. The higher percentage of referred patients in comparison to the main analysis suggests that practitioners may be more likely to consider referral when escalating therapy, but that practitioners should still consider referring patients who are already on high-dose treatment as per guideline recommendations.

The strengths of this study lie in the breadth of the coverage (as data taken from CPRD and HES records are expected to be nationally representative of the overall UK population),[@R13] quality of data (conservative approach taken to exclude missing data) and long study duration (mean follow-up period \>5 years, with a 1-year look-back period from index date).

However, there are a number of limitations. The study underestimates the number of patients with asthma that were eligible for referral, as referral criteria were based on medication use and exacerbation frequency. However, the real-world data do not assess the appropriateness of the therapy and we acknowledge there may be possible underprescription or overprescription of therapy. We did not include other referral criteria suggested in GINA and BTS/SIGN guidelines, such as diagnostic uncertainty, occupational asthma or presence of other complications. In addition, our study has excluded those patients on therapy lower than 'additional add-on' therapy at index date whose asthma may have been declining during the study period and who subsequently become eligible for referral. Eligibility criteria for referral in this study were based on the BTS/SIGN guidelines only. However, the criteria we have used are consistent across many national and international guidelines and recommendations,[@R8] including NICE asthma quality standards and GINA.[@R19] We used a long study period (2007--2015) to enrich the study population and allow sufficient follow-up time to assess referrals. However, the long study duration also meant updates were made to guidelines over the study period. Our referral criteria were based on the more recent 2016 BTS/SIGN guidelines, to ensure coverage of all the medicines that could have been used in the study period.[@R35] In addition, to operationalise the guidelines using electronic health records, we applied a pragmatic approach to therapy combinations in our allocation of patients to treatment categories. In a sensitivity analysis, we identified 1378 patients who were on exactly 800 µg ICS/LABA. However, as this was a small proportion (7%) of the eligible-for-referral population, we do not think that this significantly impacts the major findings of this study.

We acknowledge that prescription Read code indicates a prescription was made, but we cannot know whether the prescription was collected. In addition, electronic health records do not reveal whether patients have been adherent or administered their medication correctly. Additionally, prescriptions may not have been stepped down or updated after an acute exacerbation treatment. However, we believe these are limitations beyond the scope of this study, and the large data sets of CPRD and HES with robust Read codes are likely to provide an accurate representation of the unmet need in asthma referrals.

We have been able to identify that referrals are often not made, but qualitative studies are required to understand the reasons for this. Prospective studies are also needed to examine the impact of low referral rates and the extent to which the unreferred are harmed. Finally, health economics studies investigating the impact of more referrals will help inform on the balance of the cost of increasing specialist capacity compared with potentially reducing admissions and keeping people in work.

Conclusion {#s5}
==========

A significant unmet need in asthma care exists wherein the vast majority of patients who are eligible for referral based on guideline recommendations are not referred to specialist services, and those who are experience long delays. This is a potential source of preventable harm. We need to consider how we can improve compliance with guidelines while reflecting on how any increased demand would be met in secondary care. Alternatively, we can explore new models of care/recommendations.
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